We are excited about the data and plan to submit the data for publication and peer reviewed medical journal in the near term.

$AVXL Australia trial data meets the gold standard.

$AVXL - Alz Topline Data was solid ..

Efficacy is likey overwhelming after seeing 👀 data details!

$AVXL I am extremely bullish on the data .. the FDA can ask any sorts of questions

I'm looking forward to seeing the long term AD data on ANVS and have the feeling it's going to end up being the best in class AD treatment as well.

Now DATA met expectations.

Also clint said every time Blarcamesine data comes back it looks better and better. .

Anavex has significant 4 years of ph2/3 safety data with safety back to 2013 for Blarcamesine .. anavex has full 3 endpoint trial and a placebo .. it's obvious Anavex wins!!

So I think the data so far was encouraging,

$BCRX European stocks rose on Friday as investors took an optimistic view of a week of data releases that showed economies in Europe and the US were more robust than expected.

#1 Suddenly alot of positive accounts appear, promoting the company has solid data, solid sales

$BCRX Have strong feeling once 10013 data is out we are going places.

P1 data is nice ,

The data looks good.

$BCRX This preliminary data on BCX10013 is pretty impressive.

$BCRX Good 10013 data.

10013 data looks good,

$BCRX great 10013 data and 320+ projected rev

but it also seems like the good choice to do so seeing iptacopan data.

See 20+ , low float , P/E ratio , EPS , positive data .

3.67 cash per share and $20+ PT's. Not to mention, consistency with positive studies and data.

$BXRX must be good phase 2 data

This is accurate up to date short data.